Medical devices developer ResMed has closed the acquisition of digital therapeutics firm Propeller Health for a total consideration of $225m.

Propeller Health offers connected health solutions for patients with chronic obstructive pulmonary disease (COPD) and asthma.

Its portfolio comprises a digital platform with sensors that stick to consumers’ inhalers and pair with a mobile application. These sensors automatically track medication use and offer personalised feedback.

"Following the closing of the transaction, Propeller will operate as a standalone entity within ResMed’s Respiratory Care portfolio."

The deal, which was signed last month, is part of ResMed plan to broaden its range of COPD treatment solutions.

ResMed CEO Mick Farrell said: “Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalisations, and the overall cost of healthcare.”

Following the closing of the transaction, Propeller will operate as a standalone entity within ResMed’s Respiratory Care portfolio.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Propeller CEO David Van Sickle will retain his role and report to ResMed Respiratory Care president Richie McHale.

Propeller will continue to partner with pharmaceutical companies and other healthcare organisations to deliver digital therapeutics and actionable insights for people using inhalers.

The company aims to improve patients’ medication adherence, increase their number of symptom-free days and mitigate emergency room visits. Propeller expects the deal to aid in the broader use of its solutions.

Sickle said: “Joining forces enables us to accelerate the adoption of Propeller’s solutions at a global scale, and serve as a powerful platform for a broad set of pharmaceutical and healthcare partners.”